Zim Laboratories Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Zim Laboratories Ltd filed with BSE on 23 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Zim Laboratories reported full year FY26 total operating income of approximately INR 3,744 million, broadly flat versus FY25, which management attributed to an estimated INR 20-25 crore revenue impact from MENA geopolitical disruption and continued EU GMP related constraints on the regulated pipeline. The company underwent an EU GMP re-inspection by German and Portuguese authorities from May 4-7, 2026, and management said the CAPA implementation is substantially complete with a positive outcome expected. Q4 FY26 EBITDA margin was approximately 12.7% and full year PAT stood at INR 58 million, with exports contributing approximately 82% of quarterly operating income.
Numbers mentioned
Total operating income: approximately INR 1,053 million (Q4 FY26)
p. 6
“Total operating income for Q4 FY26 stood at approximately INR 1,053 million supported with strong traction in our core pharmaceutical export business.”
Shyam Mohan Patro, page 6 of the filed PDF · View the filing
EBITDA: approximately INR 134 million, margin approximately 12.7% (Q4 FY26)
p. 6
“EBITDA for the quarter stood at approximately INR 134 million translating to a margin of approximately 12.7%.”
Shyam Mohan Patro, page 6 of the filed PDF · View the filing
Profit after tax: INR 37 million (Q4 FY26)
p. 6
“Profit after tax for the Q4 stood at INR 37 million reflecting the sequential improvement compared to the previous quarters.”
Shyam Mohan Patro, page 6 of the filed PDF · View the filing
Exports as percentage of operating income: approximately 82% (Q4 FY26)
p. 6
“Exports continue to be the dominant revenue driver contributing at approximately 82% of the total operating income during the quarter.”
Shyam Mohan Patro, page 6 of the filed PDF · View the filing
NIP and OTF revenue: INR 254 million, 22% of operating income (Q4 FY26)
p. 6
“Revenue for our NIP and OTF platforms stood at INR 254 million representing 22% of the operating income.”
Shyam Mohan Patro, page 6 of the filed PDF · View the filing
Total operating income: approximately INR 3,744 million (FY26)
p. 6
“full year total operating income stood at approximately INR 3,744 million, broadly in line with FY'25.”
Shyam Mohan Patro, page 6 of the filed PDF · View the filing
EBITDA: approximately INR 414 million (FY26)
p. 6
“Full year EBITDA stood at approximately INR 414 million.”
Shyam Mohan Patro, page 6 of the filed PDF · View the filing
Profit after tax: INR 58 million (FY26)
p. 6
“Full year PAT stood at INR58 million.”
Shyam Mohan Patro, page 6 of the filed PDF · View the filing
Investment in BE studies and registrations: INR 311 million (FY26)
p. 6
“INR 311 million was allocated to BE studies and registrations advancing our NIP and OTF platform in preparation for the post EU GMP growth phase.”
Shyam Mohan Patro, page 6 of the filed PDF · View the filing
Estimated MENA revenue impact: approximately INR 20 crore (FY26)
p. 5
“We estimate a revenue impact of approximately INR 20 crore that we could have otherwise achieved from this region.”
Anwar Daud, page 5 of the filed PDF · View the filing
Preferential allotment amount: INR 35 crore at INR 73.46 per share
p. 16
“INR 35 crore was raised via preferential allotment to Florintree Trinix LLP at 73.46 per share.”
Heer Vashi, page 16 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
EU GMP certification — second quarter
stated conditionally by Zulfiquar Kamal
p. 7
“We are awaiting the EU GMP certification, which we expect somewhere in second quarter.”
Zulfiquar Kamal, page 7 of the filed PDF · View the filing
NIP product revenue commencement — fourth quarter
stated conditionally by Zulfiquar Kamal
p. 7
“And post that, NIP product, which will be giving -- expecting some revenue in the fourth quarter.”
Zulfiquar Kamal, page 7 of the filed PDF · View the filing
EBITDA margin — upper teens · 24 to 36 months
stated conditionally by Zain Daud
p. 13
“We are assuming, and we are projecting upper teens as our EBITDA margins once everything kind of starts going on in the regulated markets.”
Zain Daud, page 13 of the filed PDF · View the filing
NIP plus OTF product commercialization — Q4
stated conditionally by Zain Daud
p. 14
“So, like we said, our projection is Q4 of this year, because we'll, get our EU GMP back in the next two or three months.”
Zain Daud, page 14 of the filed PDF · View the filing
Nutraceutical business growth — 10 to 15% · every year
stated firmly by Anwar Daud
p. 15
“Yeah, 10 to 15%, we will grow. That's a fair assumption.”
Anwar Daud, page 15 of the filed PDF · View the filing
CapEx for 17 NIP/OTF products — no further capex needed
stated firmly by Zain Daud
p. 15
“No, we don't need to invest some more. We've already invested in a quite heavy CapEx cycle, and that is, almost near to completion.”
Zain Daud, page 15 of the filed PDF · View the filing
NIP revenue run rate
stated conditionally by Zain Daud
p. 20
“So, we expect this run rate to go up from here, but we will at least maintain this run rate.”
Zain Daud, page 20 of the filed PDF · View the filing
Borrowings and finance cost — this year
stated firmly by Zulfiquar Kamal
p. 21
“So, this year, perhaps the borrowing will remain constant and similarly the finance cost will also remain same.”
Zulfiquar Kamal, page 21 of the filed PDF · View the filing
NIP and OTF as percentage of revenue — 50% of the business
stated as an aspiration by Zain Daud
p. 17
“our aim is to reach to 50% of the business being coming from these innovative products and develop them RoW & Pharmerging markets.”
Zain Daud, page 17 of the filed PDF · View the filing
FY27 revenue growth and margins — mid teens margin · FY27
stated conditionally by Zulfiquar Kamal
p. 27
“So, it will be more on the mid teen side, and this is what we are projecting for the next year , Once we get CAPA and Q4 comes.”
Zulfiquar Kamal, page 27 of the filed PDF · View the filing
Gastrointestinal enzyme product scale-up — FY28
stated conditionally by Zain Daud
p. 19
“In FY28, see, we have already signed agreements for these products. So, if everything goes well, FY28 should be the full year we will be able to enjoy commercialization from this in regulated markets.”
Zain Daud, page 19 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said the EU GMP audit impacted this segment and that exact guidance cannot be given until MA timing and customer relaunch are clear.
Answered by Zulfiquar Kamal
Asked by Dharsil: Why did NIP plus OTF revenue fall and what is the addressable opportunity once resolved?
p. 8
“Yeah. So that as of today, we cannot give you exact guidance because it all depends on the timing of receiving the MA and the customer relaunching the final product in that part.”
Zulfiquar Kamal, page 8 of the filed PDF · View the filing
Management cited data integrity issues from over-reliance on manual documentation and described digitalization and automation steps taken.
Answered by Anwar Daud
Asked by Deepesh Sancheti: What was the root cause of the prior EU GMP failure and has the CAPA addressed it?
p. 10
“there were data integrity issues identified by them.”
Anwar Daud, page 10 of the filed PDF · View the filing
Management said the arrangement is a toll manufacturing charge with marginal cost impact.
Answered by Chandrashekhar Mainde
Asked by Deepesh Sancheti: What is the margin differential for the alternate CMO site versus in-house manufacturing?
p. 11
“It is not fixed. It will be very marginal. It will not be significant as we are giving it to them.”
Chandrashekhar Mainde, page 11 of the filed PDF · View the filing
Management said the split would be roughly 50% innovative products with 30% regulated and 20% ROW within that.
Answered by Zain Daud
Asked by Rupesh Tatiya: Is it fair to assume 50:50 split between regulated and ROW markets for the 17 products?
p. 13
“I think 50:50 would be the split between innovative products and our generic business.”
Zain Daud, page 13 of the filed PDF · View the filing
Management confirmed this is a sustainable minimum run rate for ROW and pharmerging markets, expected to rise further.
Answered by Zain Daud
Asked by Rohit Balakrishnan: Is the current NIP run rate of INR 17-18 crore sustainable?
p. 20
“Yeah. This is a sustainable run rate, and this is going to increase further because like we told you, we've now hired a president for international business who is looking after ROW and pharmerging markets.”
Zain Daud, page 20 of the filed PDF · View the filing
Management said the wrap-up meeting was informal and unclassified, and that they will share details once the formal report arrives.
Answered by Zain Daud
Asked by Vishal: Can shareholders get more clarity on whether the EU GMP audit found major or critical observations?
p. 23
“Yeah. See, we deliberately did not give any observations because this closing meeting is usually an informal meeting.”
Zain Daud, page 23 of the filed PDF · View the filing
Management attributed the decline to losing certain institutional tenders and said they are building a private domestic NIP/OTF business.
Answered by Zain Daud
Asked by Rohit Suresh: Why did domestic revenue decrease year on year?
p. 26
“See, the domestic business has decreased because there were some institutional business tenders, which we did not get.”
Zain Daud, page 26 of the filed PDF · View the filing
Management said base and NIP business would grow this year and guidance for H1 would be given next quarter.
Answered by Zulfiquar Kamal
Asked by Madhur Rathi: What revenue growth and margin should be expected for FY27 base business excluding EU GMP related revenue?
p. 28
“The base business and the NIP business and the percentage will definately be growing in the current year.”
Zulfiquar Kamal, page 28 of the filed PDF · View the filing
Risks flagged
MENA geopolitical conflict disrupting revenue from a strategically important region
p. 5
“The MENA region, a strategically important market for us, was significantly impacted by geopolitical disruption due to the ongoing conflict that began around February 2026.”
Anwar Daud, page 5 of the filed PDF · View the filing
EU GMP non-compliance restricting regulated market supply and revenue
p. 6
“The flat revenue performance is primarily attributed to the estimated INR 20 - 25 crore impact of MENA disruptions and continued effect of EU GMP related constraint on our regulated fair market pipeline.”
Shyam Mohan Patro, page 6 of the filed PDF · View the filing
Data integrity issues from over-dependence on manual documentation identified in prior inspection
p. 10
“Our over dependence on manual documentation and other issues was there, certainly.”
Anwar Daud, page 10 of the filed PDF · View the filing
Australian supply halted due to loss of EU GMP-based marketing authorization compliance
p. 25
“No, revenue hasn't started flowing in from there because after we got the MA, the EU GMP inspection; the last year inspection happened and we were under remediation, our Australian approval was based on EU GMP certificate.”
Zain Daud, page 25 of the filed PDF · View the filing
Loss of domestic institutional tenders due to competitive one-zero tender outcomes
p. 26
“As you know, this tender is a one zero situation, and sometimes you don't get the tender even if you quote the best price.”
Zain Daud, page 26 of the filed PDF · View the filing
Continued pancreatin shortage uncertainty pending commercialization
p. 23
“But we are looking to capitalize it as soon as possible.”
Zain Daud, page 23 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.